OncoCyte Corporation OCX

$ 2.23 0.9%

Quarterly report 2024-Q3
added 11-12-2024

OncoCyte Corporation Balance Sheet 2011-2024 | OCX

Annual Balance Sheet OncoCyte Corporation

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-3.24 M	-19 M	-6.89 M	-5.73 M	-9.66 M	-8 M	5.63 M	2.86 M	-	-
Long Term Debt	-	-	1.51 M	1.9 M	347 K	1.07 M	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	12.9 M	4.58 M	534 K	1.36 M	310 K	-	-	-	-	-
Total Current Liabilities	12.1 M	14.1 M	9 M	4.44 M	5.56 M	4.45 M	4.28 M	-	-	-	-	-
Total Liabilities	60.5 M	94.3 M	21.9 M	9.02 M	6.1 M	5.81 M	4.58 M	2.31 M	7.43 M	4.67 M	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-261 M	-188 M	-124 M	-93.7 M	-71.3 M	-54.7 M	-35.3 M	-24.1 M	-15.4 M	-10.4 M	-	-
Total Assets	100 M	160 M	55.4 M	39.9 M	9.52 M	10.2 M	14.4 M	12.7 M	6.36 M	8.29 M	-	-
Cash and Cash Equivalents	20 M	32.9 M	7.14 M	22.1 M	8.03 M	7.6 M	10.2 M	8 M	257 K	-	-	-
Book Value	39.6 M	65.2 M	33.5 M	30.8 M	3.42 M	4.4 M	9.86 M	10.4 M	-1.07 M	3.62 M	-	-
Total Shareholders Equity	34.3 M	65.2 M	33.5 M	30.8 M	3.42 M	4.4 M	9.86 M	10.4 M	-1.07 M	-	-	-

All numbers in USD currency

Quarterly Balance Sheet OncoCyte Corporation

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	196 K	221 K	221 K	19 K	39 K	58 K	77 K	100 K	134 K	187 K	-	-	187 K	1.87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	60.5 M	52 M	54.1 M	49.3 M	39.1 M	39.2 M	-	60.5 M	75.4 M	83 M	89.3 M	94.3 M	69 M	74.7 M	22.7 M	21.9 M	21.9 M	21.9 M	21.9 M	9.02 M	9.02 M	9.02 M	9.02 M	6.1 M	6.1 M	6.1 M	6.1 M	5.81 M	5.81 M	5.81 M	5.81 M	4.58 M	4.58 M	4.58 M	4.58 M	2.31 M	2.31 M	2.31 M	2.31 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-317 M	-304 M	-299 M	-290 M	-262 M	-262 M	-262 M	-261 M	-216 M	-206 M	-198 M	-188 M	-152 M	-138 M	-128 M	-124 M	-124 M	-124 M	-124 M	-93.7 M	-93.7 M	-93.7 M	-93.7 M	-71.3 M	-71.3 M	-71.3 M	-71.3 M	-54.7 M	-54.7 M	-54.7 M	-54.7 M	-35.3 M	-35.3 M	-35.3 M	-35.3 M	-24.1 M	-24.1 M	-24.1 M	-24.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	70.2 M	74.7 M	71 M	74.9 M	81.6 M	87.5 M	-	100 M	157 M	171 M	146 M	160 M	168 M	177 M	129 M	55.4 M	55.4 M	55.4 M	55.4 M	39.9 M	39.9 M	39.9 M	39.9 M	9.52 M	9.52 M	9.52 M	9.52 M	10.2 M	10.2 M	10.2 M	10.2 M	14.4 M	14.4 M	14.4 M	14.4 M	12.7 M	12.7 M	12.7 M	12.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	3.36 M	9.26 M	5.58 M	9.43 M	13.8 M	17.4 M	-	20 M	32.1 M	44.8 M	20.4 M	35.6 M	43.3 M	46.5 M	58.9 M	7.14 M	7.14 M	7.14 M	7.14 M	22.1 M	22.1 M	22.1 M	22.1 M	8.03 M	8.03 M	8.03 M	8.03 M	7.6 M	7.6 M	7.6 M	7.6 M	10.2 M	10.2 M	10.2 M	10.2 M	8 M	8 M	8 M	8 M	257 K	-	-	-	101 K	-	-	-	-	-	-	-	-	-	-	-
Book Value	9.71 M	22.7 M	16.9 M	25.6 M	42.5 M	48.3 M	-	39.6 M	81.9 M	88.1 M	57 M	65.2 M	99.3 M	103 M	107 M	33.5 M	33.5 M	33.5 M	33.5 M	30.8 M	30.8 M	30.8 M	30.8 M	3.42 M	3.42 M	3.42 M	3.42 M	4.4 M	4.4 M	4.4 M	4.4 M	9.86 M	9.86 M	9.86 M	9.86 M	10.4 M	10.4 M	10.4 M	10.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	9.71 M	22.7 M	11.6 M	20.5 M	36.1 M	42.2 M	36.5 M	34.3 M	76.9 M	83.2 M	57 M	65.2 M	99.3 M	103 M	107 M	33.5 M	33.5 M	33.5 M	33.5 M	30.8 M	30.8 M	30.8 M	30.8 M	3.42 M	3.42 M	3.42 M	3.42 M	4.4 M	4.4 M	4.4 M	4.4 M	9.86 M	9.86 M	9.86 M	9.86 M	10.4 M	10.4 M	10.4 M	10.1 M	-1.07 M	-	-	-	3.62 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency